Pioneering a new era
in inflammatory airway
Areteia Therapeutics is a clinical stage biotechnology company committed to putting respiratory patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.
Asthma is a major global healthcare problem.
- 250 million people affected
- 500 thousand deaths per year
In the U.S.:
- ~6 million doctor office visits annually
- 1.6 million emergency department visits annually
More than half of asthma patients have eosinophilic asthma, a type of asthma that is often severe and hard to treat.
people worldwide are
affected by asthma
Despite the recent approvals of new injectable biologic medicines for eosinophilic asthma, profound unmet need and burden of illness remain.
While there are an estimated 3 million U.S, and E.U. patients living with severe eosinophilic asthma, fewer than 1 in 10 of these patients are actually receiving biologic therapy today.
Half of severe asthma patients in the U.S. are hospitalized at least once annually, driving an estimated $21 billion in direct healthcare system costs.
people have severe
in the U.S. and E.U.
Our mission is to transform the challenging patient journey in eosinophilic asthma.
Our Advanced Candidate
Our lead investigational candidate is dexpramipexole, a first-in-class oral medicine that inhibits the maturation of eosinophils before they can cause damage.
Dexpramipexole’s tolerability and eosinophil-lowering efficacy have been assessed in more than 1,500 patients in multiple indications, opening the potential for the first oral treatment ever approved for eosinophilic asthma.
Constricted airway (not treated).
This eosinophilic inflammation causes damage to the bronchi (breathing tubes in the lungs), ultimately leading to the symptoms of asthma.
Open airway (treated with dexpramipexole).
Across five clinical trials spanning 10 years, dexpramipexole profoundly reduced eosinophils in blood and inflamed tissue.